New Generic Anti-depressant to be Introduced by Ranbaxy

by Dr. Enozia Vakil on March 8, 2013 at 1:59 PM
 New Generic Anti-depressant to be Introduced by Ranbaxy

Ranbaxy jumps into an in-licensing agreement with Alembic Pharmaceuticals to start marketing the generic anti-depressant drug Pristiq.

Jacksonville, Florida, base Ranbaxy Pharmaceuticals Inc (RPI) announced Tuesday that Alembic manufactured Desvenlafaxine is a bioequivalent version of Pristiq with a market size of $590 million.


India based research and development pharmaceutical company, Alembic has received the final approval from the US Food and Drug Administration (USFDA) and Ranbaxy expects the product to be available in the US marketplace during the first quarter of 2013, it said in a media release.

Commenting on the development, Bill Winter, vice president, Ranbaxy trade sales and distribution, North America said, "Ranbaxy is pleased to partner with Alembic to offer a safe, effective, affordable generic alternative to the brand formulation much ahead of the patent expiration."

"We are committed to expand our portfolio of products offered in the US market for the benefit of patients, prescribers and the US healthcare system," he said.

Source: IANS
Font : A-A+



Recommended Readings

Latest Drug News

Anti-Obesity Drugs' Impact on Osteoarthritis Survival
The impact of anti-obesity drugs on survival rates among osteoarthritis patients is under scrutiny, evaluating their potential influence on mortality risks.
Can a Needle-Free Patch Transform Zika Protection?
Researchers create needle-free Zika vaccine patch, using HD-MAP tech, aiming to protect against fatal virus spread by mosquitoes.
Prolonging Market Exclusivity of Brand-name Insulin
Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.
FDA Boosts Orphan Drug Designations for Myelofibrosis Treatments
The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.
Anti-Rheumatic Drugs May Help Prevent Thyroid Disease
The most significant decrease in autoimmune thyroid disease risk was observed in rheumatoid arthritis patients receiving immunomodulatory drugs or 'biological DMARDs'.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

New Generic Anti-depressant to be Introduced by Ranbaxy Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests